Modello socio-economico della vaccinazione anti-rotavirus nella regione di Castilla y León, Spagna

Translated title of the contribution: Socio-economic modeling of rotavirus vaccination in Castilla y León, Spain

Alberto Pérez-Rubio, Francisco Javier Luquero, Jose María Eiros Bouza, Jose Javier Castrodeza Sanz, Maria del Rosario Bachiller Luque, Raúl Ortiz de Lejarazu, Antonio Sánchez Port

Research output: Contribution to journalArticle

Abstract

Rotavirus is one of the main causes of acute gastroenteritis in infants and young children. Furthermore, rotavirus is the leading cause of hospitalization and death from acute gastroenteritis among infants and young children worldwide. Although death due to rotavirus is rare in industrialized regions such as Spain, the rotavirus disease burden and its economic impact is severe. This study aims to assess systematic vaccination against rotavirus economically and socially in a Spanish region. Economic cost-effectiveness and cost-benefit assessment through a choice tree was designed. We estimated health provider costs, economic costs and quality-adjusted life years (QALYs) lost due to rotavirus infections. The study includes a fictitious cohort of 100,000 children from Castilla y León who were also administered the rotavirus vaccine together with diphtheria and tetanus toxoids and pertussis (DTP). The study adopted a society and health care system perspective. A sensitivity analysis was developed to assess the uncertainty of some variables. According to the estimated incidence rate for children in Castilla y León, rotavirus immunization is projected to prevent 45% of cases with RotaTeq® and 57% with Rotarix®. The respective cost per QALY is about € 75,000 and 50,000 from the perspective of the health care system. Routine infant vaccination in Castilla y León using either rotavirus vaccine is not profitable from the payer's perspective and is not cost-effective under basic case assumptions unless the vaccine is available at a lower cost.

Original languageItalian
Pages (from-to)166-175
Number of pages10
JournalInfezioni in Medicina
Volume19
Issue number3
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Rotavirus
Spain
Vaccination
Economics
Rotavirus Vaccines
Costs and Cost Analysis
Quality-Adjusted Life Years
Gastroenteritis
Cost-Benefit Analysis
Diphtheria Toxoid
Delivery of Health Care
Rotavirus Infections
Tetanus Toxoid
Cost of Illness
Whooping Cough
Health Care Costs
Uncertainty
Cause of Death
Immunization
Hospitalization

Keywords

  • Cost-benefit
  • Costeffectiveness
  • Rotavirus infection
  • Vaccination

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Pérez-Rubio, A., Luquero, F. J., Bouza, J. M. E., Sanz, J. J. C., Luque, M. D. R. B., de Lejarazu, R. O., & Port, A. S. (2011). Modello socio-economico della vaccinazione anti-rotavirus nella regione di Castilla y León, Spagna. Infezioni in Medicina, 19(3), 166-175.

Modello socio-economico della vaccinazione anti-rotavirus nella regione di Castilla y León, Spagna. / Pérez-Rubio, Alberto; Luquero, Francisco Javier; Bouza, Jose María Eiros; Sanz, Jose Javier Castrodeza; Luque, Maria del Rosario Bachiller; de Lejarazu, Raúl Ortiz; Port, Antonio Sánchez.

In: Infezioni in Medicina, Vol. 19, No. 3, 09.2011, p. 166-175.

Research output: Contribution to journalArticle

Pérez-Rubio, A, Luquero, FJ, Bouza, JME, Sanz, JJC, Luque, MDRB, de Lejarazu, RO & Port, AS 2011, 'Modello socio-economico della vaccinazione anti-rotavirus nella regione di Castilla y León, Spagna', Infezioni in Medicina, vol. 19, no. 3, pp. 166-175.
Pérez-Rubio A, Luquero FJ, Bouza JME, Sanz JJC, Luque MDRB, de Lejarazu RO et al. Modello socio-economico della vaccinazione anti-rotavirus nella regione di Castilla y León, Spagna. Infezioni in Medicina. 2011 Sep;19(3):166-175.
Pérez-Rubio, Alberto ; Luquero, Francisco Javier ; Bouza, Jose María Eiros ; Sanz, Jose Javier Castrodeza ; Luque, Maria del Rosario Bachiller ; de Lejarazu, Raúl Ortiz ; Port, Antonio Sánchez. / Modello socio-economico della vaccinazione anti-rotavirus nella regione di Castilla y León, Spagna. In: Infezioni in Medicina. 2011 ; Vol. 19, No. 3. pp. 166-175.
@article{8c340a19bd664ae5ab7f5300ebc7139f,
title = "Modello socio-economico della vaccinazione anti-rotavirus nella regione di Castilla y Le{\'o}n, Spagna",
abstract = "Rotavirus is one of the main causes of acute gastroenteritis in infants and young children. Furthermore, rotavirus is the leading cause of hospitalization and death from acute gastroenteritis among infants and young children worldwide. Although death due to rotavirus is rare in industrialized regions such as Spain, the rotavirus disease burden and its economic impact is severe. This study aims to assess systematic vaccination against rotavirus economically and socially in a Spanish region. Economic cost-effectiveness and cost-benefit assessment through a choice tree was designed. We estimated health provider costs, economic costs and quality-adjusted life years (QALYs) lost due to rotavirus infections. The study includes a fictitious cohort of 100,000 children from Castilla y Le{\'o}n who were also administered the rotavirus vaccine together with diphtheria and tetanus toxoids and pertussis (DTP). The study adopted a society and health care system perspective. A sensitivity analysis was developed to assess the uncertainty of some variables. According to the estimated incidence rate for children in Castilla y Le{\'o}n, rotavirus immunization is projected to prevent 45{\%} of cases with RotaTeq{\circledR} and 57{\%} with Rotarix{\circledR}. The respective cost per QALY is about € 75,000 and 50,000 from the perspective of the health care system. Routine infant vaccination in Castilla y Le{\'o}n using either rotavirus vaccine is not profitable from the payer's perspective and is not cost-effective under basic case assumptions unless the vaccine is available at a lower cost.",
keywords = "Cost-benefit, Costeffectiveness, Rotavirus infection, Vaccination",
author = "Alberto P{\'e}rez-Rubio and Luquero, {Francisco Javier} and Bouza, {Jose Mar{\'i}a Eiros} and Sanz, {Jose Javier Castrodeza} and Luque, {Maria del Rosario Bachiller} and {de Lejarazu}, {Ra{\'u}l Ortiz} and Port, {Antonio S{\'a}nchez}",
year = "2011",
month = "9",
language = "Italian",
volume = "19",
pages = "166--175",
journal = "Infezioni in Medicina",
issn = "1124-9390",
publisher = "EDIMES Edizioni Medico Scientifiche",
number = "3",

}

TY - JOUR

T1 - Modello socio-economico della vaccinazione anti-rotavirus nella regione di Castilla y León, Spagna

AU - Pérez-Rubio, Alberto

AU - Luquero, Francisco Javier

AU - Bouza, Jose María Eiros

AU - Sanz, Jose Javier Castrodeza

AU - Luque, Maria del Rosario Bachiller

AU - de Lejarazu, Raúl Ortiz

AU - Port, Antonio Sánchez

PY - 2011/9

Y1 - 2011/9

N2 - Rotavirus is one of the main causes of acute gastroenteritis in infants and young children. Furthermore, rotavirus is the leading cause of hospitalization and death from acute gastroenteritis among infants and young children worldwide. Although death due to rotavirus is rare in industrialized regions such as Spain, the rotavirus disease burden and its economic impact is severe. This study aims to assess systematic vaccination against rotavirus economically and socially in a Spanish region. Economic cost-effectiveness and cost-benefit assessment through a choice tree was designed. We estimated health provider costs, economic costs and quality-adjusted life years (QALYs) lost due to rotavirus infections. The study includes a fictitious cohort of 100,000 children from Castilla y León who were also administered the rotavirus vaccine together with diphtheria and tetanus toxoids and pertussis (DTP). The study adopted a society and health care system perspective. A sensitivity analysis was developed to assess the uncertainty of some variables. According to the estimated incidence rate for children in Castilla y León, rotavirus immunization is projected to prevent 45% of cases with RotaTeq® and 57% with Rotarix®. The respective cost per QALY is about € 75,000 and 50,000 from the perspective of the health care system. Routine infant vaccination in Castilla y León using either rotavirus vaccine is not profitable from the payer's perspective and is not cost-effective under basic case assumptions unless the vaccine is available at a lower cost.

AB - Rotavirus is one of the main causes of acute gastroenteritis in infants and young children. Furthermore, rotavirus is the leading cause of hospitalization and death from acute gastroenteritis among infants and young children worldwide. Although death due to rotavirus is rare in industrialized regions such as Spain, the rotavirus disease burden and its economic impact is severe. This study aims to assess systematic vaccination against rotavirus economically and socially in a Spanish region. Economic cost-effectiveness and cost-benefit assessment through a choice tree was designed. We estimated health provider costs, economic costs and quality-adjusted life years (QALYs) lost due to rotavirus infections. The study includes a fictitious cohort of 100,000 children from Castilla y León who were also administered the rotavirus vaccine together with diphtheria and tetanus toxoids and pertussis (DTP). The study adopted a society and health care system perspective. A sensitivity analysis was developed to assess the uncertainty of some variables. According to the estimated incidence rate for children in Castilla y León, rotavirus immunization is projected to prevent 45% of cases with RotaTeq® and 57% with Rotarix®. The respective cost per QALY is about € 75,000 and 50,000 from the perspective of the health care system. Routine infant vaccination in Castilla y León using either rotavirus vaccine is not profitable from the payer's perspective and is not cost-effective under basic case assumptions unless the vaccine is available at a lower cost.

KW - Cost-benefit

KW - Costeffectiveness

KW - Rotavirus infection

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=80054757870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054757870&partnerID=8YFLogxK

M3 - Article

C2 - 22037437

AN - SCOPUS:80054757870

VL - 19

SP - 166

EP - 175

JO - Infezioni in Medicina

JF - Infezioni in Medicina

SN - 1124-9390

IS - 3

ER -